left-caret

Overview

Carl Minniti is an associate in the Litigation Department of Paul Hastings based in the firm’s New York office. His practice primarily focuses on complex patent, trade secret and technology-related litigation, with an emphasis on the life science, medical device and chemical sectors.

Carl has represented biotechnology companies in brand-vs.-brand litigation, contract disputes and cases arising under the Biologics Price Competition & Innovation Act and the Hatch-Waxman Act. His experience includes arguing before federal courts and the Patent Trial and Appeal Board, first-chairing offensive and defensive fact and expert witnesses, developing strategies on infringement, validity and damages issues, drafting briefs and other submissions to the court, and representing clients at trial.

Carl previously served as a law clerk to then-Chief Judge Leonard P. Stark of the U.S. District Court for the District of Delaware, who now sits on the U.S. Court of Appeals for the Federal Circuit. Before joining the firm, Carl was as a graduate fellow in the New Jersey State Senate working on legal and policy debates. He also served as a judicial intern to Judge Kent A. Jordan of the U.S. Court of Appeals for the Third Circuit, as well as Judge Gregory M. Sleet and Magistrate Judge Christopher J. Burke of the U.S. District Court for the District of Delaware.

In addition to his IP litigation practice, Carl has advised Congress on proposed legislation involving competition, patent rights and regulatory schemes in the biologics and biosimilars market. He has also collaborated with the Alliance for Artificial Intelligence in Healthcare and presented to the organization on developing intellectual property issues facing AI/ML-focused life sciences companies. Carl is currently president-elect of the New Jersey Intellectual Property Law Association.

Carl received a joint J.D./M.B.A. degree from Rutgers Law School with honors. He earned a master’s degree in Biology and B.S. degree from Saint Joseph’s University. Carl is a member of the New York Bar.

Accolades

  • Recognized for Best Academic IP Article at Antitrust Writing Awards — selected by, among others, trade commissioners from the U.S., Hong Kong and EU, in-house counsel and leading academics.
  • Published in Cornell Law Review Online, University of Illinois Law Review, American University Law Review, ABA SciTech Lawyer, Journal of the Patent & Trademark Office Society, Law360 and other legal publications.
  • "Three Antitrust Cases Drug Companies Should Watch This Year," Law360 (January 2018) (with Chad J. Peterman)
  • Carl has advised Congress on proposed legislation involving competition, patent rights and regulatory schemes in the biologics and biosimilars market.

Education

  • Rutgers Law School, J.D./M.B.A., 2017
  • Saint Joseph’s University, M.A., 2013
  • Saint Joseph’s University, B.S., 2010

Representations

  • Presently represents Allergan in patent litigation against Revance relating to Allergan’s innovations in its Botox® franchise for botulinum neurotoxin A animal protein-free formulations and manufacturing processes.
  • Presently represents Allergan in trade secret misappropriation litigation against Revance relating to botulinum neurotoxin A technology.
  • Presently represents Inpria in patent litigation matters involving chemical and semiconductor technologies.
  • JSR Life Sciences in patent litigation resulting in successful invalidation of 83 patent claims brought by Cytiva relating to protein A purification technology.
  • Boehringer Ingelheim in connection with BPCIA patent litigation relating to its biosimilar version of Humira®, which ultimately settled on favorable terms to our client.
  • L’Oréal USA in patent litigation brought by the University of Massachusetts relating to patents covering methods of using adenosine, which ultimately resulted in favorable ruling that wiped out infringement theory for all 130 L’Oréal USA products.
  • Horizon Therapeutics in Hatch-Waxman patent litigation involving generic challenge to Procysbi®, an innovative treatment used for nephropathic cystinosis, which ultimately settled on favorable terms to our client.
  • Merck in Hatch-Waxman patent litigation involving generic challenge to Entereg®, an innovative treatment used for post-operative ileus, which ultimately settled on favorable terms to our client following a favorable claim construction ruling.

    Practice Areas

    Litigation

    Intellectual Property

    Patent Litigation

    Trade Secrets

    Life Sciences and Healthcare

    Technology


    Languages

    English


    Admissions

    New York Bar


    Education

    Rutgers Law School, JD / MBA 2017

    Saint Joseph's University, M.A. 2013

    Saint Joseph's University, B.S. 2010